Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474477 | 0.84 | ALDH1A1 (0.46) | POLBKDM1AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1473344 | 0.82 | SLC6A4 (0.44) | SLC6A4SLC6A3KDM1ARCOR1EPHX2 | |
| SCHEMBL23020811 | 0.82 | OPRM1 (0.43) | POLBPKMALDH1A1LMNAMEN1 | |
| SCHEMBL1474142 | 0.81 | PDE2A (0.35) | SLC6A4SLC6A3EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1474012 | 0.81 | RORC (0.41) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL9820733 | 0.80 | MEN1 (0.45) | POLBHRH2HRH1ALDH1A1LMNA | |
| SCHEMBL1475802 | 0.80 | TSHR (0.39) | PKMALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15200618 | 0.80 | OPRM1 (0.45) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL15977383 | 0.79 | L3MBTL1 (0.49) | SLC6A4PKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15978556 | 0.79 | L3MBTL1 (0.49) | SLC6A4PKMALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | POLB 4776/4885SLC6A4 763/4885PKM 4490/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | POLB 4768/4885SLC6A4 770/4885PKM 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.